Flat ₹100 OFF on First app order | Use Code: APP100 |
Flat ₹100 OFF
on First app order
Use Code
APP100
Download Now
Congrats! you have chosen the top branded substitute.
Top Brand
Salt CompositionCefixime 400mg + Moxifloxacin 400mg
Salt CompositionCefixime 400mg + Moxifloxacin 400mg
Milixim M 400/400mg Tablet SR 5s
Glenmark Pharmaceuticals Ltd.
6+ Customers trust this
WHO GMP Certified
Assured by
Assured
Milixim M 400/400mg Tablet SR 5s
Assured by
Assured
6+ trust this
WHO GMP Certified
Customers also bought
More About Milixim-M
Benefits
In Treatment of Bacterial infections Milixim-M 400mg/400mg Tablet SR is an antibiotic medicine prescribed to treat various infections caused by bacteria such as sinus infections (sinusitis), chest infections such as bronchitis and pneumonia, and infections of the ears, skin, throat, stomach, and urinary tract. It works by stopping the growth of the bacteria. It is advisable to continue taking it as long as it is prescribed even when you feel better, to make sure that all bacteria are killed.
Side Effects
The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.
How to use
Follow your doctor's guidance regarding the dose and duration of this medication. Ingest it without breaking or crushing. Do not chew, crush or break it. Milixim-M 400mg/400mg Tablet SR can be taken it with or without food, although it's advisable to take it consistently at the same time.
How it works
Milixim-M 400mg/400mg Tablet SR is a combination of two antibiotics: Moxifloxacin and Cefixime. Moxifloxacin works by preventing the bacteria from reproducing and repairing themselves. Cefixime works by preventing the formation of the bacterial protective covering which is essential for the survival of bacteria in the human body. Together, they treat your infection effectively.
Safe: No harmful side effects are associated with consuming alcohol alongside Milixim-M 400mg/400mg Tablet SR
Seek medical advice from your doctor: Milixim-M 400mg/400mg Tablet SR may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Doctor consultation is advised.
Seek medical advice from your doctor: Milixim-M 400mg/400mg Tablet SR is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Not Safe: Milixim-M 400mg/400mg Tablet SR may cause side effects which could affect your ability to drive. Milixim-M 400mg/400mg Tablet SR may make you feel dizzy or light-headed, you may experience a sudden, transient loss of vision, or you may faint for a short period. This may affect your driving ability.
Caution Advised: Milixim-M 400mg/400mg Tablet SR should be used with caution in patients with kidney disease. Dose adjustment of Milixim-M 400mg/400mg Tablet SR may be needed. Doctor consultation is advised.
Caution Advised: Milixim-M 400mg/400mg Tablet SR should be used with caution in patients with liver disease. Dose adjustment of Milixim-M 400mg/400mg Tablet SR may be needed. Doctor consultation is advised.
What if I forget to take it?
If a dose of Milixim-M 400mg/400mg Tablet SR is missed, take it promptly. However, if your next dose is approaching, skip the missed dose and resume your regular schedule. Avoid doubling the dose.
Manufacturer Address
Glenmark Pharmaceuticals Limited, B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai ‚ 400 026.
Disclaimer
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
